10-Q · latest 10
What Idexx Laboratories's 10-Q filings say
- SEC EDGAR
10-Q
Filed · 8 signals
G&A expenses jump 18.4% driven by technology and infrastructure investments
A significant $18.1 million (18.4%) increase in G&A spending is directly attributed to investments in 'technology and infrastructure'.
$18.1M
Increase in General and administrative expense
18.4%
Increase in General and administrative expense year-over-year
Infrastructure
Veterinary software recurring revenue grows 10.7% driven by SaaS model
The company's strategic focus on a subscription model is paying off, with a 10.7% increase in recurring revenue from its expanded SaaS installed base.
$7.4M
Increase in Veterinary software, services and diagnostic imaging systems recurring revenue
10.7%
Growth in Veterinary software, services and diagnostic imaging systems recurring revenue
SaaS
Shipment delays from Middle East conflict impacted Water segment's international volumes
The Water segment experienced shipment delays in the prior quarter due to regional conflict, which affected the timing of international revenue.
IDEXX boosts Sales & Marketing spend by $10.2M for commercial expansion
The company is actively investing to expand its commercial footprint, leading to a 6.3% increase in Sales & Marketing spending on personnel, travel, and other costs.
$10.2M
Increase in Sales and marketing expense
6.3%
Increase in Sales and marketing expense year-over-year
Anticipates higher future tax rates due to US Tax Cuts and Jobs Act changes
The company warns that its effective tax rate is expected to increase due to the elimination of certain tax benefits related to share-based compensation under the Tax Cuts and Jobs Act.
Company actively shifting customers from rapid assay tests to its Catalyst instrument platform
IDEXX is managing an internal product migration, moving customers from older rapid assay tests for pancreatic lipase to its newer, more advanced Catalyst instrument platform.
- SEC EDGAR
10-Q
Filed · 9 signals
IDEXX inVue Dx Analyzer placements drive 32.7% growth in diagnostics instrument revenue
The successful rollout of the new IDEXX inVue Dx Analyzer is a primary driver of a $10.5 million increase in instrument revenue.
$10.5M
Dollar change in CAG Diagnostics capital - instruments revenue
32.7%
Reported revenue growth for CAG Diagnostics capital - instruments
Installed base of premium instruments grows 12%, driving platform adoption and consumable sales
The company's platform strategy is succeeding, with a 12% increase in its installed base of premium instruments and a deliberate shift of customers from standalone rapid assays to the integrated Catalyst instrument platform.
12%
Growth in installed base of premium instruments
Company took a $5M impairment charge for a failed equity investment in Q1 2026.
IDEXX wrote off the full value of an equity investment, resulting in a $5 million expense which contributed to a 30% increase in G&A costs.
$5M
Expense for the full impairment of an equity investment
Water segment international volumes impacted by shipping constraints from Middle East conflict.
The company is facing logistics challenges due to the conflict in the Middle East, which has directly reduced international sales volumes for its Water segment.
Showing 10 of 17 filing signals. The Signal API returns all of them.
Get them with one API callEarnings calls
Idexx Laboratories earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Raised full-year revenue and EPS guidance on strong performanceCompany increased its full-year revenue outlook by $43M and EPS by $0.33 at midpoint, signaling strong financial health and confidence to fund new initiatives and investments. | |
| Investing heavily in cloud-native PIMS and vertical SaaS platformThe company is seeing strong double-digit growth in its cloud-based software installations, now over 10,000 locations, and is investing heavily in its vertical SaaS platform as a critical part of its strategy. | |
| New Cancer Dx product is successfully winning business from competitor's customers.Leadership highlights that over 17% of Cancer Dx test submissions are from customers of competing reference labs, demonstrating a key competitive advantage and a successful 'foot-in-the-door' strategy that is taking market share. | |
| Investing in AI models for new diagnostic imaging platformThe new InVue Dx platform leverages AI models trained on over 60 million cellular images, demonstrating a significant investment and commitment to artificial intelligence to enhance its products and requiring supporting technology. | |
| Driving growth through multiple successful and upcoming product launchesStrong momentum from new products like InVue Dx (6,000 placements expected) and Catalyst Cortisol is fueling growth, with plans to expand the Cancer Dx platform, creating needs across R&D, supply chain, and marketing. | |
| Facing market headwinds from a 2.5% decline in U.S. wellness visits.The decline in routine wellness visits due to macro pressures is a key business challenge, making the company receptive to solutions that drive patient engagement, visit frequency, and overall market growth. |
Signal API · MCP
Track Idexx Laboratories with the Signal API
One POST /v1/companies/enrich call with idexx.com returns Idexx Laboratories 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"idexx.com","signal_types":["sec-10q"],"limit":20}'Same industry
10-Q at related companies
Questions about Idexx Laboratories 10-Q
When did Idexx Laboratories file its latest 10-Q?
What did Idexx Laboratories disclose in its latest 10-Q?
What did Idexx Laboratories say on its recent earnings calls?
Where can I read Idexx Laboratories's 10-Q filing?
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .